Two successful examples of targeted therapies in pediatric leukemia include tyrosine kinase inhibitors in BCR-ABL-positive ALL (4) and all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APML) with the PML–RARα fusion (5). Here, RARA is linked to acute promyelocytic leukemia.